Veru (VERU) Competitors

Veru logo
$1.94 -0.17 (-8.06%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.96 +0.02 (+0.88%)
As of 11/20/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

VERU vs. DERM, MENS, ZNTL, CRDL, and NERV

Should you buy Veru stock or one of its competitors? Veru's main competitors and comparable companies include Journey Medical (DERM), Jyong Biotech (MENS), Zentalis Pharmaceuticals (ZNTL), Cardiol Therapeutics (CRDL), and Minerva Neurosciences (NERV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Veru compare to Journey Medical?

Veru (NASDAQ:VERU) and Journey Medical (NASDAQ:DERM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Veru presently has a consensus price target of $24.50, indicating a potential upside of 1,162.89%. Journey Medical has a consensus price target of $13.00, indicating a potential upside of 295.14%. Given Veru's stronger consensus rating and higher possible upside, equities analysts clearly believe Veru is more favorable than Journey Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veru
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Journey Medical
2 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00

Journey Medical has higher revenue and earnings than Veru. Journey Medical is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veru$16.89M1.96-$22.73M-$0.69N/A
Journey Medical$61.86M1.50-$11.43M-$0.18N/A

Veru has a net margin of 0.00% compared to Journey Medical's net margin of -7.34%. Journey Medical's return on equity of -16.07% beat Veru's return on equity.

Company Net Margins Return on Equity Return on Assets
VeruN/A -47.58% -35.83%
Journey Medical -7.34%-16.07%-5.26%

47.2% of Veru shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 14.2% of Veru shares are owned by company insiders. Comparatively, 14.5% of Journey Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Journey Medical had 5 more articles in the media than Veru. MarketBeat recorded 12 mentions for Journey Medical and 7 mentions for Veru. Journey Medical's average media sentiment score of -0.07 beat Veru's score of -0.21 indicating that Journey Medical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veru
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Journey Medical
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Veru has a beta of -1.2, suggesting that its share price is 220% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

Summary

Journey Medical beats Veru on 9 of the 16 factors compared between the two stocks.

How does Veru compare to Jyong Biotech?

Jyong Biotech (NASDAQ:MENS) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

47.2% of Veru shares are owned by institutional investors. 14.2% of Veru shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Veru had 7 more articles in the media than Jyong Biotech. MarketBeat recorded 7 mentions for Veru and 0 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 0.00 beat Veru's score of -0.21 indicating that Jyong Biotech is being referred to more favorably in the media.

Company Overall Sentiment
Jyong Biotech Neutral
Veru Neutral

Veru has a consensus target price of $24.50, indicating a potential upside of 1,162.89%. Given Veru's stronger consensus rating and higher probable upside, analysts plainly believe Veru is more favorable than Jyong Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jyong Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Veru
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Jyong Biotech has higher earnings, but lower revenue than Veru.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jyong BiotechN/AN/A-$4.67MN/AN/A
Veru$16.89M1.96-$22.73M-$0.69N/A

Jyong Biotech has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market. Comparatively, Veru has a beta of -1.2, suggesting that its stock price is 220% less volatile than the broader market.

Jyong Biotech's return on equity of 0.00% beat Veru's return on equity.

Company Net Margins Return on Equity Return on Assets
Jyong BiotechN/A N/A N/A
Veru N/A -47.58%-35.83%

Summary

Veru beats Jyong Biotech on 7 of the 12 factors compared between the two stocks.

How does Veru compare to Zentalis Pharmaceuticals?

Veru (NASDAQ:VERU) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

Veru's return on equity of -47.58% beat Zentalis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
VeruN/A -47.58% -35.83%
Zentalis Pharmaceuticals N/A -75.82%-55.15%

In the previous week, Veru had 7 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 7 mentions for Veru and 0 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.39 beat Veru's score of -0.21 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Veru Neutral
Zentalis Pharmaceuticals Neutral

47.2% of Veru shares are held by institutional investors. 14.2% of Veru shares are held by insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Veru presently has a consensus price target of $24.50, suggesting a potential upside of 1,162.89%. Zentalis Pharmaceuticals has a consensus price target of $8.29, suggesting a potential upside of 509.24%. Given Veru's higher possible upside, equities research analysts clearly believe Veru is more favorable than Zentalis Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veru
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Zentalis Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80

Veru has a beta of -1.2, meaning that its share price is 220% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.91, meaning that its share price is 91% more volatile than the broader market.

Veru has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Veru is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veru$16.89M1.96-$22.73M-$0.69N/A
Zentalis Pharmaceuticals$67.43M1.98-$137.06M-$1.92N/A

Summary

Veru and Zentalis Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Veru compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Cardiol Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 1,059.29%. Veru has a consensus target price of $24.50, indicating a potential upside of 1,162.89%. Given Veru's higher possible upside, analysts clearly believe Veru is more favorable than Cardiol Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiol Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Veru
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Veru's return on equity of -47.58% beat Cardiol Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cardiol TherapeuticsN/A -159.81% -127.69%
Veru N/A -47.58%-35.83%

In the previous week, Cardiol Therapeutics had 4 more articles in the media than Veru. MarketBeat recorded 11 mentions for Cardiol Therapeutics and 7 mentions for Veru. Cardiol Therapeutics' average media sentiment score of -0.05 beat Veru's score of -0.21 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cardiol Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Veru
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

Veru has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiol TherapeuticsN/AN/A-$24.20M-$0.24N/A
Veru$16.89M1.96-$22.73M-$0.69N/A

Cardiol Therapeutics has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, Veru has a beta of -1.2, indicating that its stock price is 220% less volatile than the broader market.

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 47.2% of Veru shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by company insiders. Comparatively, 14.2% of Veru shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Veru beats Cardiol Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Veru compare to Minerva Neurosciences?

Minerva Neurosciences (NASDAQ:NERV) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

Veru has higher revenue and earnings than Minerva Neurosciences. Veru is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Minerva NeurosciencesN/AN/A-$293.42M-$28.70N/A
Veru$16.89M1.96-$22.73M-$0.69N/A

Minerva Neurosciences' return on equity of 0.00% beat Veru's return on equity.

Company Net Margins Return on Equity Return on Assets
Minerva NeurosciencesN/A N/A -28.95%
Veru N/A -47.58%-35.83%

In the previous week, Veru had 4 more articles in the media than Minerva Neurosciences. MarketBeat recorded 7 mentions for Veru and 3 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.89 beat Veru's score of -0.21 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Minerva Neurosciences
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Veru
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

Minerva Neurosciences has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market. Comparatively, Veru has a beta of -1.2, indicating that its stock price is 220% less volatile than the broader market.

34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 1.7% of Minerva Neurosciences shares are owned by insiders. Comparatively, 14.2% of Veru shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Minerva Neurosciences currently has a consensus price target of $10.33, indicating a potential upside of 416.67%. Veru has a consensus price target of $24.50, indicating a potential upside of 1,162.89%. Given Veru's stronger consensus rating and higher probable upside, analysts plainly believe Veru is more favorable than Minerva Neurosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Minerva Neurosciences
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Veru
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Veru beats Minerva Neurosciences on 9 of the 14 factors compared between the two stocks.

Get Veru News Delivered to You Automatically

Sign up to receive the latest news and ratings for VERU and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VERU vs. The Competition

MetricVeruPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$33.08M$13.12B$7.44B$10.86B
Dividend YieldN/A2.62%2.51%4.68%
P/E Ratio-2.8127.8232.5628.68
Price / Sales1.966.977.665.19
Price / CashN/A15.2220.2520.77
Price / Book1.555.164.343.51
Net Income-$22.73M$2.86B$3.51B$394.12M
7 Day Performance-7.18%-7.27%-8.07%-8.97%
1 Month Performance-15.28%-9.60%-10.29%-11.61%
1 Year Performance-12.61%-9.28%-4.70%-11.21%

Veru Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VERU
Veru
1.6482 of 5 stars
$1.94
-8.1%
$24.50
+1,162.9%
-12.6%$33.08M$16.89MN/A20
DERM
Journey Medical
1.6657 of 5 stars
$4.52
+1.1%
$14.00
+209.7%
-55.9%$133.50M$61.86MN/A58
MENS
Jyong Biotech
N/A$1.85
+2.8%
N/A-95.3%$132.29MN/AN/A27
ZNTL
Zentalis Pharmaceuticals
3.7236 of 5 stars
$1.74
+1.2%
$7.75
+345.4%
+1.5%$126.14M$67.43MN/A106
CRDL
Cardiol Therapeutics
2.3261 of 5 stars
$1.03
+3.5%
$10.00
+870.9%
-11.3%$122.83MN/AN/A18

Related Companies and Tools


This page (NASDAQ:VERU) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners